<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03605147</url>
  </required_header>
  <id_info>
    <org_study_id>CIR-CAHMB-001</org_study_id>
    <nct_id>NCT03605147</nct_id>
  </id_info>
  <brief_title>The Effect of Calcium β-hydroxy-β-methylbutyrate (CaHMB) Supplementation in Sarcopenia in Liver Cirrhosis</brief_title>
  <acronym>CaHMB</acronym>
  <official_title>The Effect of Calcium β-hydroxy-β-methylbutyrate Supplementation in Sarcopenia in Liver Cirrhosis：A Randomized Double-blind Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Zhongshan Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Zhongshan Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to evaluate the effect of CaHMB in the treatment of sarcopenia in liver
      cirrhosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is a randomized double-blind controlled trial. Patients randomly enter into two
      treatment groups: 1) the CaHMB group and 2) the placebo group. Treatment allocation is by
      block randomization, with an one-to-one ratio for CaHMB and placebo. The results are
      concealed in opaque envelopes. Patients will report their daily diets with an online
      software. Patients will come for clinic after 4 weeks and 12 weeks, receiving laboratory
      tests and sarcopenia evaluation, and events of primary and secondary outcomes will be
      analyzed.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 22, 2018</start_date>
  <completion_date type="Anticipated">July 2019</completion_date>
  <primary_completion_date type="Anticipated">July 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in skeletal muscle mass</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Changes of total muscle mass at the level of L3 in CT, analysed by the total cross-sectional area of muscle in centimetres squared (cm2)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in total body weight</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Change of total body weight .</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Grip strength</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Changes of grip strength of both hands measured with a grip dynamometer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Protein metabolic markers</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Changes of protein metabolic makers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in intramuscular fat deposition</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Changes of mean muscle attenuation (MA) at the level of L3 in CT</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Sarcopenia</condition>
  <condition>Cirrhosis, Liver</condition>
  <arm_group>
    <arm_group_label>CaHMB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CaHMB Group (n=60) will receive CaHMB twice a day and a late evening snack every night for 12 weeks. A specialized, ready-to-drink liquid with 34 kcal, 8.5 g carbohydrate, 1.5g calcium-HMB. The late evening snack is a drink with low-Glycemic Index carbohydrate with 112 kcal.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Control Group (n=60) will receive placebo twice a day and placebo every night for 12 weeks with similar composition but without HMB. The late evening snack is a drink with low-Glycemic Index carbohydrate with 112 kcal.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>CaHMB</intervention_name>
    <description>Supplements, labeled only with the identification number of the participant, will be provided to the participants in the Department of Gastroenterology of Zhongshan Hospital. After 4 weeks, subjects will receive medical center visit to evaluate the compliance and side effects. After 12 weeks, changes in body composition will be assessed by abdominal CT. An online application will be used to monitor the compliance everyday.Their diets will be recorded by a nutritionist. Blood will be collected pre- and post treatment. Extensive laboratory tests will be performed.</description>
    <arm_group_label>CaHMB</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Supplements, labeled only with the identification number of the participant, will be provided to the participants in the Department of Gastroenterology of Zhongshan Hospital. After 4 weeks, subjects will receive medical center visit to evaluate the compliance and side effects. After 12 weeks, changes in body composition will be assessed by CT. An online application will be used to monitor the compliance everyday.Their diets will be recorded by a nutritionist. Blood will be collected pre- and post treatment. Extensive laboratory tests will be performed.</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. diagnosed of cirrhosis with imaging or liver biopsy;

          2. diagnosis of portal hypertension with endoscopy or radiography；

          3. assessed total muscle mass at the level of L3 (&lt;42 cm2/m2 for male and &lt;38 cm2/m2 for
             female)

          4. has signed an informed consent form.

        Exclusion Criteria:

          1. diagnosed as hepatic cell cancer;

          2. complicated with malignancy, renal failure, diabetes mellitus;

          3. comorbidities including heart failure or pulmonary disease;

          4. current use of drugs that affect skeletal muscle metabolism;

          5. be allergic to the experimental food;

          6. participated other clinical trials in the past 3 months;

          7. other conditions that researchers consider not suitable for this study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shiyao Chen, doctor</last_name>
    <role>Study Chair</role>
    <affiliation>Fudan University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ji Zhou, doctor</last_name>
    <phone>86 18221868695</phone>
    <email>zhouji_fudan@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Shiyao Chen, doctor</last_name>
    <phone>86 13601767310</phone>
    <email>syaochen@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Shanghai Zhongshan Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ji Zhou, doctor</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Chan HL, Jia J. Chronic hepatitis B in Asia-new insights from the past decade. J Gastroenterol Hepatol. 2011 Jan;26 Suppl 1:131-7. doi: 10.1111/j.1440-1746.2010.06544.x. Review.</citation>
    <PMID>21199524</PMID>
  </reference>
  <reference>
    <citation>Holeček M. Beta-hydroxy-beta-methylbutyrate supplementation and skeletal muscle in healthy and muscle-wasting conditions. J Cachexia Sarcopenia Muscle. 2017 Aug;8(4):529-541. doi: 10.1002/jcsm.12208. Epub 2017 May 10. Review.</citation>
    <PMID>28493406</PMID>
  </reference>
  <reference>
    <citation>Sinclair M, Gow PJ, Grossmann M, Angus PW. Review article: sarcopenia in cirrhosis--aetiology, implications and potential therapeutic interventions. Aliment Pharmacol Ther. 2016 Apr;43(7):765-77. doi: 10.1111/apt.13549. Epub 2016 Feb 5. Review.</citation>
    <PMID>26847265</PMID>
  </reference>
  <reference>
    <citation>Baumgartner RN, Koehler KM, Gallagher D, Romero L, Heymsfield SB, Ross RR, Garry PJ, Lindeman RD. Epidemiology of sarcopenia among the elderly in New Mexico. Am J Epidemiol. 1998 Apr 15;147(8):755-63. Erratum in: Am J Epidemiol 1999 Jun 15;149(12):1161.</citation>
    <PMID>9554417</PMID>
  </reference>
  <reference>
    <citation>Cruz-Jentoft AJ, Baeyens JP, Bauer JM, Boirie Y, Cederholm T, Landi F, Martin FC, Michel JP, Rolland Y, Schneider SM, Topinková E, Vandewoude M, Zamboni M; European Working Group on Sarcopenia in Older People. Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older People. Age Ageing. 2010 Jul;39(4):412-23. doi: 10.1093/ageing/afq034. Epub 2010 Apr 13.</citation>
    <PMID>20392703</PMID>
  </reference>
  <reference>
    <citation>Tsien C, Davuluri G, Singh D, Allawy A, Ten Have GA, Thapaliya S, Schulze JM, Barnes D, McCullough AJ, Engelen MP, Deutz NE, Dasarathy S. Metabolic and molecular responses to leucine-enriched branched chain amino acid supplementation in the skeletal muscle of alcoholic cirrhosis. Hepatology. 2015 Jun;61(6):2018-29. doi: 10.1002/hep.27717. Epub 2015 Feb 27.</citation>
    <PMID>25613922</PMID>
  </reference>
  <reference>
    <citation>Wilkinson DJ, Hossain T, Limb MC, Phillips BE, Lund J, Williams JP, Brook MS, Cegielski J, Philp A, Ashcroft S, Rathmacher JA, Szewczyk NJ, Smith K, Atherton PJ. Impact of the calcium form of β-hydroxy-β-methylbutyrate upon human skeletal muscle protein metabolism. Clin Nutr. 2018 Dec;37(6 Pt A):2068-2075. doi: 10.1016/j.clnu.2017.09.024. Epub 2017 Oct 6.</citation>
    <PMID>29097038</PMID>
  </reference>
  <reference>
    <citation>Tsien CD, McCullough AJ, Dasarathy S. Late evening snack: exploiting a period of anabolic opportunity in cirrhosis. J Gastroenterol Hepatol. 2012 Mar;27(3):430-41. doi: 10.1111/j.1440-1746.2011.06951.x. Review.</citation>
    <PMID>22004479</PMID>
  </reference>
  <reference>
    <citation>Takaguchi K, Moriwaki H, Doyama H, Iida M, Yagura M, Shimada N, Kang M, Yamada H, Kumada H. Effects of branched-chain amino acid granules on serum albumin level and prognosis are dependent on treatment adherence in patients with liver cirrhosis. Hepatol Res. 2013 May;43(5):459-66. doi: 10.1111/j.1872-034X.2012.01097.x. Epub 2012 Oct 10.</citation>
    <PMID>23046471</PMID>
  </reference>
  <reference>
    <citation>Plank LD, Gane EJ, Peng S, Muthu C, Mathur S, Gillanders L, McIlroy K, Donaghy AJ, McCall JL. Nocturnal nutritional supplementation improves total body protein status of patients with liver cirrhosis: a randomized 12-month trial. Hepatology. 2008 Aug;48(2):557-66. doi: 10.1002/hep.22367.</citation>
    <PMID>18627001</PMID>
  </reference>
  <reference>
    <citation>Nishikawa H, Shiraki M, Hiramatsu A, Moriya K, Hino K, Nishiguchi S. Japan Society of Hepatology guidelines for sarcopenia in liver disease (1st edition): Recommendation from the working group for creation of sarcopenia assessment criteria. Hepatol Res. 2016 Sep;46(10):951-63. doi: 10.1111/hepr.12774.</citation>
    <PMID>27481650</PMID>
  </reference>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>July 22, 2018</study_first_submitted>
  <study_first_submitted_qc>July 27, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 30, 2018</study_first_posted>
  <last_update_submitted>September 25, 2018</last_update_submitted>
  <last_update_submitted_qc>September 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HMB</keyword>
  <keyword>sarcopenia</keyword>
  <keyword>liver cirrhosis</keyword>
  <keyword>chronic liver disease</keyword>
  <keyword>malnutrition</keyword>
  <keyword>muscle wasting</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Sarcopenia</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

